Wanchaijiraboon Passakorn, Teeyapun Nattaya, Pakvisal Nussara, Sainamthip Panot, Susiriwatananont Thiti, Zungsontiporn Nicha, Suntronwong Nungruthai, Vichaiwattana Preeyaporn, Klinsawat Worata, Wanlapakorn Nasamon, Tanasanvimon Suebpong, Sriuranpong Virote, Poovorawan Yong, Luangdilok Sutima
Phrapokklao Cancer Center of Excellence, Phrapokklao Clinical Research Center, Phrapokklao Genomic Laboratories, Phrapokklao Hospital, Mueang District, Chanthaburi 22000, Thailand.
The King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand.
Vaccines (Basel). 2022 Oct 5;10(10):1662. doi: 10.3390/vaccines10101662.
There are limited data available about the durability of the immune response after administration of the widely used adenovirus-vectored ChAdOx1-nCoV-19 vaccine in cancer patients. This prospective longitudinal observational study analyzed follow-up data of immunogenic responses 12 weeks after the second dose of the ChAdOx1-nCoV-19 vaccine in 290 oncological patients compared to healthy controls. The study aimed to assess the persistence of the humoral immune response three months after the second dose, and omicron neutralization was also evaluated. Three months after completion of the second vaccine dose, the geometric mean titer of SARS-CoV-2 binding total Ig statistically decreased by 42% compared to those at 4 weeks, and was lower than that of the healthy control. Six percent of patients became seronegative for anti-RBD total Ig. Only 5% (2 of 40 samples) tested positive for surrogate neutralization against SAR-CoV-2 Omicron BA.2. Across different therapy types, a waning in immunogenicity was observed within three months after the second dose of the ChAdOx1 nCoV-19 vaccine, rendering it insufficient at that point to protect against the SAR-CoV-2 Omicron BA.2 variant.
关于广泛使用的腺病毒载体ChAdOx1-nCoV-19疫苗在癌症患者中接种后免疫反应的持久性，现有数据有限。这项前瞻性纵向观察研究分析了290名肿瘤患者在接种第二剂ChAdOx1-nCoV-19疫苗12周后的免疫原性反应的随访数据，并与健康对照进行比较。该研究旨在评估第二剂疫苗接种三个月后体液免疫反应的持续性，同时也评估了对奥密克戎的中和作用。在完成第二剂疫苗接种三个月后，SARS-CoV-2结合总Ig的几何平均滴度与4周时相比，统计学上下降了42%，且低于健康对照。6%的患者抗RBD总Ig血清学转为阴性。仅5%（40份样本中的2份）对针对SARS-CoV-2奥密克戎BA.2的替代中和试验呈阳性。在不同治疗类型中，在接种第二剂ChAdOx1 nCoV-19疫苗三个月内观察到免疫原性减弱，这使得此时不足以预防SARS-CoV-2奥密克戎BA.2变体。
